HBIO: harvardbioscience.com Projected Price to Earnings

Harvard Bioscience creates a unique toolkit for global laboratories, facilitating cell research and drug synthesis. Production relies on ESG standards, waste minimization, and energy efficiency. Pricing policy is balanced by scientist loyalty and the cost-reduction needs of biotech startups. The company's forward P/E ratio clearly demonstrates market earnings expectations, where the 213.20 mark serves as a key metric.

HBIO - Harvard Bioscience, Inc. Market Cap to Projected Earnings over the range 07/04/2022 - 11/11/2026

Analytical breakdowns and data insights for company harvardbioscience.com (HBIO)

- stock value and consensus price forecast:

Price Chart Harvard Bioscience|HBIO - Price Target Chart

- market capitalization information:

Market Valuation Harvard Bioscience Inc.|HBIO - Value Adjusted for Debt and Cash

- issuer book value statistics:

Book Value per Share Harvard Bioscience|HBIO - Book Valuation of Business|Market Value to Book Value Ratio harvardbioscience.com|HBIO - Total Business Assets

- debt burden and liquidity indicators:

Debt to Equity Harvard Bioscience|HBIO - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio Harvard Bioscience, Inc.|HBIO - Company Cumulative Indebtedness|Debt to Book Capitalization Ratio Harvard Bioscience Inc.|HBIO - Company Long-Term Loans and Borrowings|Company Current Liabilities Harvard Bioscience|Quick Liquidity harvardbioscience.com

- earnings and market ratios statistics:

HBIO - Net Income|Projected Future Earnings Harvard Bioscience|HBIO - Market Cap to Earnings|Future Price to Earnings Harvard Bioscience|HBIO - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio Harvard Bioscience Inc.|HBIO - Company profit before taxes, interest and amortization|Earnings per share for the last twelve months Harvard Bioscience|HBIO - Net earnings per share for the last four quarters|Quarterly EPS earnings growth harvardbioscience.com|HBIO - Earnings per share increase in current year|Earnings growth forecast for next year Harvard Bioscience

Summary company analysis:HBIO Harvard Bioscience

Signature product of Harvard Bioscience Inc.

Forward P/E measures a stock's market value relative to projected net income, allowing for an assessment of the premium paid for future earnings. Analyzing the forward P/E valuation of Harvard Bioscience (HBIO) helps determine entry points, given that the large-scale robotization of HBIO assembly lines and the implementation of computer vision systems should optimize costs, thereby fundamentally justifying profit growth and the asset's current value.

Direct competitors